6,678 trials
Fabry's Disease
Primary: Percent Reduction in Shortest Tolerated Infusion Duration From Pre-study Average of Recent 3 Infusions — 84.19 percent
Dry Eye
Primary: Mean Change From Baseline (CFB) in Dry Eye Symptom Severity at Visit 3 — -44.5 score on a scale
Complex Insomnia
Primary: Change in Pittsburgh Sleep Quality Index (PSQI) (32) at 6 Months Post-randomization — -5.25; -5.45 units on a scale — p=0.05
Laparotomy · Colectomy
Primary: Cumulative Opioid Consumption Over 48 Hours — 33; 61 morphine milligram equivalents
Postpartum Hemorrhage · Uterine Atony
Primary: Uterine Tone Score — 4.7; 4.4 score on a scale
Musculoskeletal Pain · Analgesia · Adverse Event
Primary: Mean Difference of Visual Analog Scale Scores — -29.74; -29.85 score on a scale
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Radial Artery Spasm
Primary: Number of Participants With Clinical Radial Artery Spasm (RAS) — 23; 3 participants
Congenital Hemangioma · Hemangioendothelioma · Angiosarcoma
Primary: Adverse Drug Reactions During the Embolization Procedure — 0 Participants
Acne Vulgaris
Primary: The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on IGA at Week 16. — 65 percentage of participants
Heart Failure · Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Flow-Mediated Dilation (FMD) — 3.61; 3.66; 4.22; 3.55 % increase from pre-occlusion value
HIV-1-infection · Solid Organ Transplant
Primary: Change in Pharmacokinetic Parameters (Cmax, Cmin) of CsA Immunosuppressant — 825; 299; 86.5; 98.5 ng/mL
Metastatic Solid Tumors
Primary: Percentage of Participants Experiencing Any Adverse Events — 66.7; 100.0; 91.7 percentage of participants
Anterior Cruciate Ligament Tear · Knee Meniscus Tear
Primary: Change in Quadriceps Strength Related to the Nerve Block — -0.42; -0.55; -3.19; -0.77 Newtons
Deep Vein Thrombosis · Pulmonary Embolism · Venous Thromboembolism
Primary: Frequency of Symptomatic, Recurrent VTE Defined as the Composite of Deep Vein Thrombosis and/or Pulmonary Embolism — 4; 30 Participants